Virology and Oncology

Genoscience Pharma was founded in 2001 by Pr Philippe Halfon, a world renowned medical expert on viral diseases, especially on Human Immunodeficient Virus (HIV) and Hepatitis C Virus (HCV). The company was initially focused on the development of anti-HCV agents. Two protease inhibitors were thus developed and out-licensed to BioLineRX.
A new scientific direction was taken in 2012 after the discovery of a new chemical family: autophagy inhibitors. Following promising preliminary in vitro and in vivo results from these small molecules, including against cancer stem cells, Genoscience Pharma has decided to take the opportunity to make the difference in Oncology, especially in cancers where medical needs are still unmet. Now, Genoscience Pharma is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer.

“After the approval of treatments truly capable of curing patients with Hepatitis C, many patients still visited me at hospital. As a physician, I had to explain them that they may later suffer from liver cancer. I had to do my best to propose them some alternative : I then decided to use my previous experience and knowledge in viral liver diseases to make things better in Oncology.”

Philippe HalfonPhysician, CEO & Founder at Genoscience Pharma
Company Inception
Inception by Pr Philippe Halfon and Dr Jean-Marc Feryn.2001
Out-licensing of two HCV protease inhibitors to BioLineRX.2007-2012
New Therapeutic Area
New scientific direction in Oncology after the discovery of autophagy inhibitors effective against many in vitro cancer models.2012
GNS561 Preclinical Development
Successful regulatory development for GNS561 to get US FDA Investigational New Drug (IND) and EMA Clinical Trial Application (CTA).2015-2018
Series A Funding
Capital increase of 10 million euros by US-based business angels from pharmaceutical industry.2016
Clinical Stage Company
Initiation of a global Phase 1b/2a study with GNS561 in patients with primary liver cancer.2018
Expansion of GNS561 Indications
Expansion of Phase 1b/2a with GNS561 to patients with secondary liver cancer (pancreatic and colorectal cancers with liver mestastasis).2019
Expansion to COVID-19
Launch of a Phase 2 program in mild to moderate patients infected by SARS-CoV-2

Stopped in 20212020

Oncology Phases 2
Phase 2 in HCC (FR) & iCCA (US/EU)


Orphan Drug Designation from FDA
Obtained in January 2023 for HCC

& in 2022 for iCCA2023